Skip to main content
padlock icon - secure page this page is secure

To Preliminarily Evaluate The Anticancer Activiy of 1,2-di(quinazolin-4- yl)diselane Against MDA-MB-435 Cells in vitro

Buy Article:

$68.00 + tax (Refund Policy)

Breast cancer is the most common invasive cancer among women and a main cause of human death. Chemotherapy drugs play a key role in breast cancer treatment. The current main problems in chemotherapy are drug toxicity and drug resistance. The discovery of antitumor drugs suitable for breast cancer therapy remains one of principal challenges. In our recent anticancer drug discovery screen, 1,2-di(quinazolin-4-yl)diselane (LG003) was found to possess wide spectrum anticancer efficacy. In the present work, the in vitro anticancer activity of LG003 was evaluated in metastatic breast cancer cell line MDA-MB-435. Compared with commercial anticancer drug Gefitinib, Oxaliplatin, Epirubicin Hydrochloride, 10-Hydroxycamptothecin and Taxol, LG003 exhibited better or similar antitumor activity which suggests that LG003 may be a potential anticancer agent for breast cancer. Further treatment time and dose tests indicated LG003 inhibited MDA-MB-435 cells in time- and dose-dependent way. Direct morphological observation showed that LG003 treatment resulted in the decrease in cell population size, then apoptosis like shrinking and blebbing, cell membrane damage and crumbling in turn in a time- and dose-dependent manner. Lactate Dehydrogenase release assay revealed that LG003 executed such effect in MDA-MB-435 cells partly through cytotoxicity which suggests that title compound LG003 can be used as lead compound for the design and synthesis of more active and low toxicity anticancer drugs for breast cancer treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 1; 2-di(quinazolin-4-yl)diselane; MDA-MB-435; anticancer activity; anticancer agent; breast cancer; cytotoxicity

Document Type: Research Article

Publication date: November 1, 2014

More about this publication?
  • Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more